Skip to content

Advertisement

Articles

Page 5 of 33

  1. Content type: Research article

    The expansion of antigen-specific CD8 T cells is important in generating an effective and long-lasting immune response to tumors and viruses. Glucocorticoid-induced tumor necrosis factor receptor family-relate...

    Authors: Nick M. Durham, Nick Holoweckyj, Randall S. MacGill, Kelly McGlinchey, Ching Ching Leow and Scott H. Robbins

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:47

    Published on:

  2. Content type: Research article

    Adoptive cellular therapy (ACT) with cancer antigen-reactive T cells following lymphodepletive pre-conditioning has emerged as a potentially curative therapy for patients with advanced cancers. However, identi...

    Authors: Weiqing Jing, Jill A. Gershan, Grace C. Blitzer, Katie Palen, James Weber, Laura McOlash, Matthew Riese and Bryon D. Johnson

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:51

    Published on:

  3. Content type: Review

    This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November...

    Authors: Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky Jr., Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:50

    Published on:

  4. Content type: Research article

    Accumulating pre-clinical data indicate that the efficient induction of antigen-specific cytotoxic CD8+ T cells characterizing viral infections is caused by cross-priming where initially infected DCs produce a...

    Authors: Anna Laurell, Maria Lönnemark, Einar Brekkan, Anders Magnusson, Anna Tolf, Anna Carin Wallgren, Bengt Andersson, Lars Adamson, Rolf Kiessling and Alex Karlsson-Parra

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:52

    Published on:

  5. Content type: Case report

    Stimulation of the immune system by targeting the PD-1/PD-L1 pathway can result in activation of anti-tumor immunity. Besides its clinical benefit immune checkpoint therapy leads to significant immune-related ...

    Authors: Heinz Läubli, Jürgen Hench, Michal Stanczak, Ingmar Heijnen, Alexandros Papachristofilou, Stephan Frank, Alfred Zippelius and Frank Stenner-Liewen

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:46

    Published on:

  6. Content type: Case report

    Immunotherapy plays a key role in the treatment of metastatic melanoma. Patients with autoimmune conditions and/or on immunosuppressive therapy due to orthotropic transplants, however, are systematically exclu...

    Authors: Gustavo Schvartsman, Kristen Perez, Jill E. Flynn, Jeffrey N. Myers and Hussein Tawbi

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:45

    Published on:

  7. Content type: Erratum

    Authors: Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez and Constantin N. Baxevanis

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:48

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2017 5:39

  8. Content type: Research article

    Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pe...

    Authors: Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis and Julie A. Stone

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:43

    Published on:

  9. Content type: Research article

    Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. T...

    Authors: Dina Schneider, Ying Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, Andrew Kaiser, Boro Dropulic and Rimas J. Orentas

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:42

    Published on:

  10. Content type: Review

    As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic...

    Authors: Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton and Lisa H. Butterfield

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:44

    Published on:

  11. Content type: Case report

    Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence ...

    Authors: James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D. Rao, Ranee Mehra and Colleen Veloski

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:40

    Published on:

  12. Content type: Commentary

    Tumor cells can be detected and cleared by lymphocytes in a process termed cancer immunosurveillance. However, the contributing cell types had not been fully characterized. Using oncogene-induced murine models...

    Authors: Saïda Dadi and Ming O. Li

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:41

    Published on:

  13. Content type: Research article

    Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor ...

    Authors: Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:35

    Published on:

  14. Content type: Research article

    Studies assessing immune parameters typically utilize human PBMCs or murine splenocytes to generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory CD4-T ce...

    Authors: Gail D. Sckisel, Annie Mirsoian, Christine M. Minnar, Marka Crittenden, Brendan Curti, Jane Q. Chen, Bruce R. Blazar, Alexander D. Borowsky, Arta M. Monjazeb and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:33

    Published on:

  15. Content type: Research article

    Testicular cancer is the most common male neoplasm occurring in men between the ages of 20 and 34. Although germ-line testicular tumors respond favorably to current standard of care, testicular stromal cell (T...

    Authors: Robert Aguilar, Justin M. Johnson, Patrick Barrett and Vincent K. Tuohy

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:37

    Published on:

  16. Content type: Meeting report

    As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a ...

    Authors: Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton and Peter P. Yu

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:38

    Published on:

  17. Content type: Research article

    We have been developing a non-thermal, drug-free tumor therapy called Nano-Pulse Stimulation (NPS) that delivers ultrashort electric pulses to tumor cells which eliminates the tumor and inhibits secondary tumo...

    Authors: Richard Nuccitelli, Amanda McDaniel, Snjezana Anand, John Cha, Zachary Mallon, Jon Casey Berridge and Darrin Uecker

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:32

    Published on:

  18. Content type: Research article

    Exercise immunology has become a growing field in the past 20 years, with an emphasis on understanding how different forms of exercise affect immune function. Mechanistic studies are beginning to shed light on...

    Authors: Michael P. Gustafson, Ara Celi DiCostanzo, Courtney M. Wheatley, Chul-Ho Kim, Svetlana Bornschlegl, Dennis A. Gastineau, Bruce D. Johnson and Allan B. Dietz

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:30

    Published on:

  19. Content type: Research article

    Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...

    Authors: Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez and Constantin N. Baxevanis

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:39

    Published on:

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:48

  20. Content type: Case report

    Prostate cancer is one of the most common cancers in men and the fourth leading cause of cancer mortality worldwide. Although major progress has been achieved in the last years for patients with metastatic cas...

    Authors: Luc Cabel, Elika Loir, Gwenaelle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albiges, Giulia Baciarello, Yohann Loriot and Karim Fizazi

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:31

    Published on:

  21. Content type: Case report

    Myelophthisis due to melanoma is a rare phenomenon. Treatment strategies for patients with this serious complication of malignancy have not been well documented, and none have previously reported efficacy of i...

    Authors: Samuel Rosner, Filiz Sen and Michael Postow

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:34

    Published on:

  22. Content type: Review

    Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in ...

    Authors: David F. Stroncek, Lisa H. Butterfield, Michael A. Cannarile, Madhav V. Dhodapkar, Tim F. Greten, Jean Charles Grivel, David R. Kaufman, Heidi H. Kong, Firouzeh Korangy, Peter P. Lee, Francesco Marincola, Sergio Rutella, Janet C. Siebert, Giorgio Trinchieri and Barbara Seliger

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:21

    Published on:

  23. Content type: Meeting report

    This report summarizes the symposium, ‘Immunotherapy Biomarkers 2016: Overcoming the Barriers’, which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cospon...

    Authors: James L. Gulley, Jay A. Berzofsky, Marcus O. Butler, Alessandra Cesano, Bernard A. Fox, Sacha Gnjatic, Sylvia Janetzki, Shyam Kalavar, Vaios Karanikas, Samir N. Khleif, Ilan Kirsch, Peter P. Lee, Cristina Maccalli, Holden Maecker, Jeffrey Schlom, Barbara Seliger…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:29

    Published on:

  24. Content type: Research article

    T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined. Here we report results ...

    Authors: Kristen M. Hege, Emily K. Bergsland, George A. Fisher, John J. Nemunaitis, Robert S. Warren, James G. McArthur, Andy A. Lin, Jeffrey Schlom, Carl H. June and Stephen A. Sherwin

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:22

    Published on:

  25. Content type: Research article

    Insufficient persistence and effector function of chimeric antigen receptor (CAR)-redirected T cells have been challenging issues for adoptive T cell therapy. Generating potent CAR T cells is of increasing imp...

    Authors: Ryan Urak, Miriam Walter, Laura Lim, ChingLam W. Wong, Lihua E. Budde, Sandra Thomas, Stephen J. Forman and Xiuli Wang

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:26

    Published on:

  26. Content type: Research article

    Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (...

    Authors: James W. Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M. Neumeister, Mario Sznol, Harriet M. Kluger and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:25

    Published on:

  27. Content type: Commentary

    Immune checkpoint inhibitors have emerged as a promising therapeutic option for metastatic cancers. However, they have been associated with inflammatory adverse reactions in various organ systems. A recent art...

    Authors: Marc-Elie Nader, Jeffrey N. Myers and Paul W. Gidley

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:24

    Published on:

  28. Content type: Short report

    Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic...

    Authors: Evan J. Lipson, Mohammed T. Lilo, Aleksandra Ogurtsova, Jessica Esandrio, Haiying Xu, Patricia Brothers, Megan Schollenberger, William H. Sharfman and Janis M. Taube

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:23

    Published on:

  29. Content type: Case report

    CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor clinically targeted for use in cancer treatment. It is expressed exclusively on T-cells where its primary role is t...

    Authors: Jeanelle King, Javier de la Cruz and Jose Lutzky

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:19

    Published on:

  30. Content type: Research article

    Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate wit...

    Authors: Gray Kueberuwa, Hannah Gornall, Erik Marcelo Alcantar-Orozco, Deborah Bouvier, Zainul Abedin Kapacee, Robert Edward Hawkins and David Edward Gilham

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:14

    Published on:

  31. Content type: Research article

    Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with...

    Authors: Mohanad H. Nada, Hong Wang, Grefachew Workalemahu, Yoshimasa Tanaka and Craig T. Morita

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:9

    Published on:

  32. Content type: Review

    Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent yea...

    Authors: Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton and Jedd D. Wolchok

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:16

    Published on:

  33. Content type: Research article

    Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the in...

    Authors: Patrick Danaher, Sarah Warren, Lucas Dennis, Leonard D’Amico, Andrew White, Mary L. Disis, Melissa A. Geller, Kunle Odunsi, Joseph Beechem and Steven P. Fling

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:18

    Published on:

  34. Content type: Research article

    Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-depend...

    Authors: Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley and Jeffrey Schlom

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:20

    Published on:

  35. Content type: Case report

    Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-...

    Authors: Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Ozgun, Ciara Kelly, Meredith McKean, Jennifer McQuade, Mary Ann Thompson, Igor Puzanov, John P. Greer, Suthee Rapisuwon, Michael Postow, Michael A. Davies, Zeynep Eroglu and Douglas Johnson

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:8

    Published on:

  36. Content type: Case report

    Allogeneic hematopoietic stem cell transplantation and checkpoint blockade therapy are immune-based therapies that have activity in selected refractory hematologic malignancies. Interest has developed in combi...

    Authors: James Godfrey, Michael R. Bishop, Sahr Syed, Elizabeth Hyjek and Justin Kline

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:11

    Published on:

  37. Content type: Case report

    Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed...

    Authors: Uqba Khan, Humaira Rizvi, Dahlia Sano, Jane Chiu and Tarik Hadid

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:13

    Published on:

  38. Content type: Case report

    Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-...

    Authors: Uqba Khan, Farman Ali, Muhammad Siddique Khurram, Awais Zaka and Tarik Hadid

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:15

    Published on:

  39. Content type: Erratum

    Authors: Marc Uemura, Faisal Fa’ak, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff and Adi Diab

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:7

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2016 4:55

  40. Content type: Research article

    We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune resp...

    Authors: Gilda G. Hillman, Lyndsey A. Reich, Shoshana E. Rothstein, Lisa M. Abernathy, Matthew D. Fountain, Kali Hankerd, Christopher K. Yunker, Joseph T. Rakowski, Eric Quemeneur and Philippe Slos

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:4

    Published on:

  41. Content type: Case report

    Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by thes...

    Authors: Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka and Jose Lutzky

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:3

    Published on:

  42. Content type: Case report

    Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases a...

    Authors: Kathryn E. Beckermann, Pradeep C. Jolly, Ju Y. Kim, Jennifer Bordeaux, Igor Puzanov, W. Kimryn Rathmell and Douglas B. Johnson

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:1

    Published on:

2017 Journal Metrics

Advertisement